Estrogen and Xenoestrogens in Breast Cancer
Authors:
Open Access
- 21 November 2009
- journal article
- research article
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 38 (1) , 110-122
Abstract
There is growing concern that estrogenic environmental compounds that act as endocrine-disrupting chemicals might potentially have adverse effects on hormone-sensitive organs such as the breast. This concern is further fueled by evidence indicating that natural estrogens, specifically 17β-estradiol, are important factors in the initiation and progression of breast cancer. We have developed an in vitro—in vivo model in which we have demonstrated the carcinogenicity of E2 in human breast epithelial cells MCF-10F. Hypermethylation of NRG1, STXBP6, BMP6, CSS3, SPRY1, and SNIP were found at different progression stages in this model. The use of this powerful and unique model has provided a tool for exploring whether bisphenol A and butyl benzyl phthalate have relevance in the initiation of breast cancer. These studies provide firsthand evidence that the natural estrogen 17β-estradiol and xenoestrogenic substances like bisphenol A are able to induce neoplastic transformation in human breast epithelial cells.Keywords
This publication has 76 references indexed in Scilit:
- Epithelial to Mesenchymal Transition in Human Breast Epithelial Cells Transformed by 17β-EstradiolCancer Research, 2007
- Urinary Concentrations of Bisphenol A and 4-Nonylphenol in a Human Reference PopulationEnvironmental Health Perspectives, 2005
- Hormone replacement therapy and incidence of hormone‐dependent cancers in the Norwegian Women and Cancer studyInternational Journal of Cancer, 2004
- Impaired differentiation and lactational failure ofErbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5Development, 2003
- Breast cancer and hormone-replacement therapy in the Million Women StudyThe Lancet, 2003
- Parent Bisphenol A Accumulation in the Human Maternal-Fetal-Placental UnitEnvironmental Health Perspectives, 2002
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- HER4 Mediates Ligand-Dependent Antiproliferative and Differentiation Responses in Human Breast Cancer CellsMolecular and Cellular Biology, 2001
- Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancerThe Lancet, 1997
- Estrogenicity of resin-based composites and sealants used in dentistry.Environmental Health Perspectives, 1996